How to buy VBI Vaccines shares

VBI Vaccines Inc is a biotechnology business with stocks listed in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$3.28 – an increase of 1.55% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in VBI Vaccines

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for VBI Vaccines. Find the share by name or ticker symbol: VBIV. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VBI Vaccines reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$3.28, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of VBI Vaccines, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of VBI Vaccines. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

US stocks

eToro Share Trading (US stocks)

Finder Award

Our top pick for

Cheap broker fees

IG Share Trading

Finder Award

Our top pick for

Long-term investing

CMC Markets Stockbroking

Finder Award

VBI Vaccines share price

Compare share trading platforms to buy stock

Sort by:

Name	Product	Standard brokerage for US shares	Inactivity fee	Currency conversion fee	Markets
eToro Share Trading (US stocks) Finder Award		US$0	US$10 per month if there’s been no login for 12 months	0.50%	US shares, ETFs	Zero brokerage share trading on US stocks with trades as low as $50. Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.	Go to site More Info	Compare	loading Fetching your data...
IG Share Trading Finder Award		US$0	$50 per quarter if you make fewer than three trades in that period	0.70%	ASX shares, Global shares	$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares. Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.	Go to site More Info	Compare	loading Fetching your data...
Saxo Capital Markets (Classic account) Finder Award		US$9.9	No	0.75%	ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs	Acess 19,000+ stocks on 37 exchanges worldwide Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.	Go to site More Info	Compare	loading Fetching your data...
CMC Markets Stockbroking Finder Award		US$0	No	0.60%	ASX shares, Global shares, mFunds, ETFs	$0 brokerage on global shares including US, UK and Japan markets. Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.	Go to site More Info	Compare	loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

Is it a good time to buy VBI Vaccines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Shorting VBI Vaccines shares

There are currently 35.2 million VBI Vaccines shares held short by investors – that's known as VBI Vaccines's "short interest". This figure is 8.8% down from 38.6 million last month.

There are a few different ways that this level of interest in shorting VBI Vaccines shares can be evaluated.

VBI Vaccines's "short interest ratio" (SIR)

VBI Vaccines's "short interest ratio" (SIR) is the quantity of VBI Vaccines shares currently shorted divided by the average quantity of VBI Vaccines shares traded daily (recently around 2.8 million). VBI Vaccines's SIR currently stands at 12.7. In other words for every 100,000 VBI Vaccines shares traded daily on the market, roughly 12700 shares are currently held short.

However VBI Vaccines's short interest can also be evaluated against the total number of VBI Vaccines shares, or, against the total number of tradable VBI Vaccines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VBI Vaccines's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 VBI Vaccines shares in existence, roughly 140 shares are currently held short) or 0.1909% of the tradable shares (for every 100,000 tradable VBI Vaccines shares, roughly 191 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against VBI Vaccines.

Find out more about how you can short VBI Vaccines stock.

VBI Vaccines share dividends

We're not expecting VBI Vaccines to pay a dividend over the next 12 months.

Have VBI Vaccines's shares ever split?

VBI Vaccines's shares were split on a 1:40 basis on 1 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.

VBI Vaccines share price volatility

Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as US$2.06 up to US$6.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.9967. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

VBI Vaccines overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of VBI Vaccines is owned by insiders or institutions?

  Currently 3.274% of VBI Vaccines shares are held by insiders and 52.916% by institutions.

• When does the fiscal year end for VBI Vaccines?

  VBI Vaccines's fiscal year ends in December.

• Where is VBI Vaccines based?

  VBI Vaccines's address is: 222 Third Street, Cambridge, MA, United States, 02142

• What is VBI Vaccines's ISIN number?

  VBI Vaccines's international securities identification number is: CA91822J1030

• What is VBI Vaccines's CUSIP number?

  VBI Vaccines's Committee on Uniform Securities Identification Procedures number is: 91822J103